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Abstract
Background: Medulloblastoma is a highly malignant pediatric brain tumor that requires surgery, whole brain and
spine irradiation, and intense chemotherapy for treatment. A more sophisticated understanding of the
pathophysiology of medulloblastoma is needed to successfully reduce the intensity of treatment and improve
outcomes. Nuclear factor kappa-B (NFB) is a signaling pathway that controls transcriptional activation of genes
important for tight regulation of many cellular processes and is aberrantly expressed in many types of cancer.
Methods: To test the importance of NFB to medulloblastoma cell growth, the effects of multiple drugs that
inhibit NFB, pyrrolidine dithiocarbamate, diethyldithiocarbamate, sulfasalazine, curcumin and bortezomib, were
studied in medulloblastoma cell lines compared to a malignant glioma cell line and normal neurons. Expression of
endogenous NFB was investigated in cultured cells, xenograft flank tumors, and primary human tumor samples. A
dominant negative construct for the endogenous inhibitor of NFB, IB, was prepared from medulloblastoma cell
lines and flank tumors were established to allow specific pathway inhibition.
Results: We report high constitutive activity of the canonical NFB pathway, as seen by Western analysis of the
NFB subunit p65, in medulloblastoma tumors compared to normal brain. The p65 subunit of NFB is extremely
highly expressed in xenograft tumors from human medulloblastoma cell lines; though, conversely, the same cells
in culture have minimal expression without specific stimulation. We demonstrate that pharmacological inhibition of
NFB in cell lines halts proliferation and leads to apoptosis. We show by immunohistochemical stain that
phosphorylated p65 is found in the majority of primary tumor cells examined. Finally, expression of a dominant
negative form of the endogenous inhibitor of NFB, dnIB, resulted in poor xenograft tumor growth, with average
tumor volumes 40% smaller than controls.
Conclusions: These data collectively demonstrate that NFB signaling is important for medulloblastoma tumor
growth, and that inhibition can reduce tumor size and viability in vivo. We discuss the implications of NFB
signaling on the approach to managing patients with medulloblastoma in order to improve clinical outcomes.
Background
Medulloblastoma is largely a cancer of children, with
75-80% of cases diagnosed in individuals younger than
fifteen years; some are diagnosed in infancy [1-3]. It is a
very aggressive and invasive cancer which spreads pri-
marily via cerebral spinal fluid to metastasize anywhere
in the leptomeninges, or, in advanced disease, hemato-
genously to invade any body part. It is suspected to
arise from cerebellar granule cell precursors [1,4] based
on its primitive neuronal histology and location in the
midline posterior fossa. Survival is achievable in many
children, dependent on a number of factors, yet recur-
rence holds a dismal prognosis [3]. Current understand-
ing of the biology of medulloblastoma cannot fully
provide an explanation for medulloblastoma occurrence,
proliferative properties, migratory activity, or che-
motherapy resistance.
Prognosis has improved over the last half century with
the addition of radiation therapy and chemotherapy. In
spite of these advances, there remains a considerable
unmet need to increase survival rates, especially in high-
risk disease. Further, targeted therapies need to be iden-
tified such that normal developing brain tissue will be
spared, thereby avoiding the disabling sequelae which
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goals are more likely to be achieved through better
understanding of the biology of the disease and exploit-
ing features unique to the tumor rather than by the cur-
rent strategy of damaging tumor cells more than normal
cells.
Despite comprehensive studies to identify risk factors
associated with medulloblastoma, no environmental risk
factor has been linked to development of medulloblas-
toma. A variety of chromosomal abnormalities have
been reported, and defects in signaling pathways such as
Wingless (Wnt) and sonic hedgehog (SHH) have been
identified in some sporadic and heritable forms of
medulloblastoma [1,3,5], but these represent a minority
of cases.
Current research pertaining to cancer and immune
response has revealed an association between nuclear
factor kappa B (NFB) signaling and tumorigenesis.
Over the past 25 years, NFB has been described and
characterized through a wide range of normal and
pathologic model systems [6]. NFBi saf a m i l yo ft r a n -
scription factors that regulate genes involved in cell
growth, apoptotic cell death, adhesion and angiogenesis.
Although only the related viral oncogene v-rel is acutely
transforming, growing evidence implicates nearly all
members of the NFB family in human malignancy
[7,8]. Chromosomal abnormalities within the genes of
these transcription factors are found in many solid and
hematopoietic tumors. Also, many cancers have muta-
tions affecting the activity of upstream regulators [6].
Moreover, many forms of leukemia and a wide variety
of solid tumors demonstrate constitutive activation of
this otherwise tightly regulated pathway [9] by increas-
ing pathway stimulation or by inactivating negative feed-
back molecules [9,10]. Some of the most aggressive
malignancies of childhood, including neuroblastoma,
rhabdomyosarcoma, Wilms tumor, and retinoblastoma
have also been reported to involve NFB.
NFB is normally quiescent in cells and only becomes
activated in response to stress signals such as pro-
inflammatory cytokines. In the canonical NFB pathway,
a heterodimer consisting of two subunits, p65 (RelA)
and p50, is sequestered in the cytoplasm by an inhibi-
tory protein, IB-a, under normal physiological condi-
tions. Upon induction of the pathway, the inhibitor IB-
a becomes phosphorylated by an IBk i n a s e( I K K ) ,
which leads to ubiquitination of IB. The inhibitor is
thus targeted to the ubiquitin-proteasome for degrada-
tion, and the NFB heterodimer p65/p50 is free to
translocate to the nucleus and begin altering gene
expression [10,11]. Some specific downstream NFB tar-
gets include survival genes Bcl-xl and XIAP; adhesion
molecules ICAM-1, VCAM-1 and ELAM-1; metastasis
promoting gene MMP-9; angiogenesis factors VEGF and
TNFa; proliferation genes cyclin D1 and C-myc; and a
host of other genes known for their association with
proliferation, inflammation, and immortalization of cells
[6,10,12].
Because of the prominence NFB signaling has gained
in adult cancer research and evidence of its activity in
some high grade pediatric malignancies, we have asked
whether this pathway could be a dominant feature of
medulloblastoma. Our studies have established that p65
is indeed over expressed in primary tumor samples and
in tumor cell lines. Furthermore, multiple drugs that
inhibit NFB cause apoptotic cell death in all four cell
lines tested. Finally, disruption of NFB signaling using
a dominant negative variant of the endogenous inhibitor
of NFB, dnIB, resulted in reduced xenograft tumor
growth. We have, therefore, established that NFB plays
a role in medulloblastoma and that it may be a target
for therapeutic intervention.
Methods
Chemicals
All chemicals were obtained from Sigma-Aldrich, St.
Louis, MO unless otherwise indicated. Stocks were pre-
pared as follows: curcumin, 10 mM in ethanol; bortezo-
mib (LC laboratories, Woburn, MA), 200 mg/mL in
DMSO, then diluted to 10 mM in phosphate buffered
saline (PBS) pH 7.4; pyrrolidine dithiocarbamate ammo-
nium salt (PDTC), 10 mM in PBS; diethyldithiocarba-
mate sodium salt (DDTC), 10 mM in PBS; sulfasalazine
(SAS) 10 mM in 0.1 M saline, pH7.4; doxycycline, 10
μg/mL in sterile water; TNFa (R&D Systems, Minnea-
polis, MD), 100 μg/mL in sterile PBS+0.1% bovine
serum albumin.
Cell Culture
Experiments using cultured medulloblastoma cells were
performed on two commercially available cell lines,
Daoy and D283, (American Type Culture Collection,
Manassas, VA) and two cell lines, D425 and D458
[13,14], established from primary medulloblastomas
( k i n d l yp r o v i d e db yD r .D .B i g n e r ,D u k eU n i v e r s i t y ,
Durham, NC). Cell cultures were maintained in MEMa
supplemented with 2 mM L-glutamine (Mediatech,
Manassas, VA) and 10% characterized fetal bovine
s e r u m( F B S )( H y C l o n e ,L o g a n ,U T ) ,o ri nR i c h t e r ’s
improved MEM Zinc Option containing 10 mM HEPES
and 0.22% sodium bicarbonate (Life Technologies), 2
mM L-glutamine, and 10% FBS. U-87MG Grade III
glioma cell line (kindly provided by Dr. D. Bigner, Duke
University, Durham, NC) was grown in Dulbecco’s
Modification of Eagle’s Medium/F-12 supplemented
with 7% FBS and 2 mM L-glutamine (Mediatech).
Mouse neurospheres were derived from embryonic day
14 mouse cortex (StemCell Technologies Inc, British
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Cult NSC Basal Medium with 10% NeuroCult NSC Pro-
liferation Supplements (StemCell Technologies); 20 ng/
mL rhEGF was added just before use. All medulloblas-
toma cells and neurospheres were maintained at 37°C in
a9 5 %O 2-5% CO2 humidified atmosphere; U-87MG
cells were incubated in 90%O2-10%CO2.
Proliferation assays
Cells were seeded in 24-well dishes at densities that had
been determined to allow for exponential growth for the
duration of the experiment. For the time course, cells
were left untreated or were treated for 3 days at the
IC90 for each line (325 nM PDTC for Daoy and 350
nM for D425). Cells were counted using a Beckman
Multisizer 3 Coulter counter. For dose-response experi-
ments, cells were grown for 3-4 days in the absence or
presence of varying concentrations of each drug and
counted as above.
Annexin-V staining
Apoptosis was measured with annexin V-Cy3 staining,
following manufacturer’s instructions (BioVision Inc,
Mountain View, CA). At least 100 cells were counted
for each experiment. Positively staining cells in each low
power field were identified by fluorescence microscopy.
The number of positive cells was divided by the total
number of cells in those fields and reported as % posi-
tive for annexin V.
Tissue
Human autopsy tissue was obtained from the University
of Alabama at Birmingham (UAB) Tissue Collection and
Banking Facility, Cooperative Human Tissue Network
Southern Division. Smo/Smo transgenic medulloblas-
toma mice with constitutive expression of Smoothened
in cerebellar granule neurons [4] were generously pro-
vided by Dr. Jim Olson, Fred Hutchinson Cancer
Research Center, Seattle, WA. All studies were per-
formed in accordance with standards of the UAB Insti-
tutional Review Board (IRBN080731009, X070829010).
Whole cell or total tissue lysates
Cell pellets collected from 10 cm culture dishes were
rinsed in PBS and lysed in RIPA (50 mM Tris-HCl pH
8.0, 150 mM NaCl, 1% IGEPAL detergent, 0.1% SDS,
0.5% Na
+ deoxycholate) containing 1X final concentra-
tion protease and phosphatase inhibitors (Sigma-
Aldrich). Tissues (10-30 mg) were homogenized on ice
in lysis buffer (100 mM Tris-HCl pH 7.4, 1% SDS) con-
taining protease and phosphatase inhibitors. Samples
were sonicated briefly, incubated at 4°C with occasional
agitation for 1 hour, then clarified by centrifugation at
14,000 X g for 30 minutes at 4°C. Proteins were
quantified using the modified detergent-compatible
Lowry assay (BioRad Laboratories, Hercules, CA).
Nuclear and Cytoplasmic extracts
Frozen tissue was homogenized in cavitation buffer
(5 mM HEPES, pH 7.4; 3 mM MgCl2;1m ME G T A ;
250 mM sucrose) containing protease and phosphatase
inhibitor cocktails (Sigma-Aldrich) and 0.1 μMo k a d a i c
acid (Alexis Biochemicals, San Diego, CA). Cell lysis was
achieved by nitrogen cavitation (250 psi, 5 minutes on
ice). The resulting lysate was centrifuged at 700 relative
centrifugal force (rcf) for 10 minutes. Cytosolic fractions
were obtained by centrifuging the low-speed supernatant
at 16,000 rcf for one hour. Nuclei were purified from
the low-speed pellet by washing twice in cavitation buf-
fer at 2700 rcf for 5 minutes each. The washes were
repeated in cavitation buffer containing 0.5% IGEPAL
detergent (Sigma-Aldrich), and then the pellet was
resuspended and loaded onto a 1 M continuous sucrose
gradient prior to centrifugation at 4°C, 2700 rcf for
10 minutes. The pellet was recovered and the sucrose
gradient repeated, followed by a wash in cavitation buffer
containing detergent for 5 minutes at 2700 rcf, and then
a final wash in cavitation buffer without detergent for
5 minutes at 16,000 rcf. Extracts were obtained from the
purified nuclei by resuspending in lysis buffer (10 mM
Tris pH 7.4, 150 mM NaCl, 1mM EGTA, 1 mM EDTA,
1 mM IGEPAL detergent) containing protease and phos-
phatase inhibitors (Sigma-Aldrich) and agitating at 4°C
for 30 minutes. Nuclear extracts were clarified by centri-
fugation at 16,000 rcf for 30 minutes at 4°C.
Nuclear and cytoplasmic extracts of cultured cells or
frozen tissue were also obtained using the Pierce NE-
PER kit according to manufacturer’s instructions
(Thermo Scientific Pierce Protein Research Products,
Rockford, IL). Cells were either untreated, or were trea-
ted for 30 minutes with 15 ng/mL TNFa. Proteins were
quantified as above.
Western Blots
Fifteen to 20 micrograms total protein per lane were
separated on 10%, 12%, or 15% SDS PAGE gels and
transferred to PVDF membranes (Millipore, Billerica,
MA). Membranes were blocked in TBS-T (20 mM Tris-
HCl pH 7.6, 137 mM NaCl, 0.1% Tween-20) containing
5% nonfat dry milk for 1 hour at room temperature. Pri-
mary antibodies were applied overnight at 4°C in TBS-T
+5% milk. Primary antibodies included: NFBs u b u n i t
p65, (Santa Cruz Biotechnology, Inc, Santa Cruz, CA);
phosphorylated (S536 or S276) NFB subunit p65, (Cell
S i g n a l i n gT e c h n o l o g y ,D a n v e r s ,M A ) ;I B-a (Santa
Cruz); tubulin (Abcam Inc, Cambridge, MA); histones
(Chemicon/Millipore) (MAb 052); actin (Sigma-Aldrich);
cleaved caspase 3 (Cell Signaling). After extensive
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ate secondary antibody (goat anti-mouse or goat anti-
rabbit-HRP conjugate, Santa Cruz) at room temperature
for one hour. Detection was accomplished with ECL
plus detection reagent (GE Healthcare Biosciences,
Piscataway, NJ) and images were collected on a Kodak
Image Station 4000MM. Membranes were stripped for
1 hour at 50°C in strip buffer (62.5 mM Tris-HCl pH
6.7, 2% SDS, 100 mM b-mercaptoethanol), rinsed exten-
sively in TBS-T, and re-probed as needed.
Immunohistochemistry
Slides of human primary medulloblastoma were
obtained from the Cooperative Human Tissue Network
Pediatric Division (Columbus Children’sH o s p i t a l ,
Columbus, OH). The sections were deparaffinized in
Citrisolv (Fisher Scientific, Pittsburgh, PA) and a stan-
dard citrate buffer antigen retrieval technique [15] was
used to unmask protein epitopes. After blocking, the
sections were incubated in phos(S276)p65 primary anti-
body (Cell Signaling, Boston, MA) overnight at °C. After
washing, sections were incubated in an HRP-conjugated
goat anti-rabbit secondary antibody at room tempera-
ture for 1 hour. Biotin tyramide (NEN Life Science Pro-
ducts, Perkin Elmer, Waltham, MA) signal amplification
was used to enhance detection with the avidin biotin
complex (ABC) method (Vector Laboratories, Burlin-
game, CA) and diaminobenzidine (Sigma-Aldrich) chro-
magen substrate. The sections were counterstained with
hematoxylin. These studies were performed at the UAB
Neuroscience Molecular Detection Core, supported by
P30 NS47466.
DNA construct
A dominant negative form of IB-a (S32A and S36A)
was amplified from the plasmid pCMV-dnIBaM (Clon-
tech, Mountain View, CA) and cloned into the pTRE-
Tight-Bi-AcGFP1 vector (Clontech) at the KpnI and
NotI sites to create pTRE-Tight-Bi-AcGFP-dnIB (Addi-
tional File 1 A). This vector co-expresses AcGFP with
dnIB from a bidirectional promoter upon activation of
the tet response element. Sequences were confirmed by
automated sequencing.
Double-stable cell line 4H10
D425 cells were first transfected with the pTet-off plas-
mid (Clontech) to create a tet-responsive line expressing
the tTA protein. Cells were transfected with Lipofecta-
mine at a 1:5 DNA to Lipofectamine ratio according to
the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). The cells were incubated overnight with the Lipo-
fectamine/DNA complexes, and the next day cells were
washed to remove the DNA. Twenty four hours later
cells were re-plated in a 6-well dish for selection with
0.4 mg/mL geneticin (Invitrogen). After 10 days, cells
were expanded to a 6 cm dish, and a week later colonies
were isolated using cloning disks (RPI) and expanded for
testing. Clones were evaluated for expression of tTA
using a luciferase assay (see below). Selection was main-
tained at 0.1 mg/mL geneticin.
The double stable cell line expressing dnIBa n d
AcGFP under control of the tet response element was
created by transfecting the D425 tet off cell line with
the pTRE-Tight-Bi-AcGFP-dnIB construct and a linear
hygromycin marker (Clontech) in a 10:1 ratio as above.
Clones were selected by limiting dilution in 96-well
dishes using 0.2 mg/mL hygromycin B (EMD Bios-
ciences, Gibbstown, NJ). Doxycycline (DOX) (Sigma-
Aldrich) was included at 100 ng-1 μg/mL to repress
expression of dnIB. Clones were expanded and tested
by FACS (UAB CFAR Flow Cytometry Core) for expres-
sion of AcGFP by washing out DOX as follows. Cells
were harvested, washed twice in PBS, and re-plated in
fresh media containing no DOX. Three to 6 hours later
the media was replaced again. The clone displaying the
highest fluorescence, 4H10, was further evaluated; selec-
tion was maintained at 0.1 mg/mL hygromycin.
Luciferase assays
Tet off clonal cell lines were evaluated for expression of
tTA by transiently transfecting with the reporter plas-
mid pTRE-HA-Luc (Clontech) using Lipofectamine as
above. The next day cells were washed and split into 2
identical wells, and DOX was added to one well at 2 μg/
mL. The following day, cells were washed and incubated
with beetle luciferin (Promega, Madison, WI) and lumi-
nescence was measured on a LumiStar luminometer
(BMG Labtech, Japan). Cells were then counted and
luminescence was normalized to cell number. Fold
induction was calculated as relative luciferase units
(RLU): RLU (No DOX)/RLU (DOX). A cell line with
greater than 20 fold induction and little to no back-
ground was selected for further work.
Double stable cell lines expressing dnIB under con-
trol of the tet response element were evaluated for bio-
logical response by transiently transfecting with the
reporter plasmid p5X NFB-Luc using Lipofectamine as
described. The next day, DNA-containing medium was
removed and cells were cultured in 100 ng/mL DOX or
washed as described above to remove DOX. Two days
later, cells were collected and assayed for luciferase
activity as above.
Xenografts in athymic mice
Twenty-four 6-8 week old female athymic mice were
randomized to two arms, DOX or No DOX. Mice in the
DOX arm received mouse pellets containing 200 mg/kg
[16] DOX (Bio-Serv, Frenchtown, NJ) for 1 week prior
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toma cells containing dnIB construct) were cultured in
100 ng/mL DOX until 24 hours prior to injection of
flank tumors. DOX was washed out of half the cells as
described above for injection into mice in the No DOX
arm. One million cells were resuspended in 200 μLo fa
solution containing 50% serum-free media and 50%
Matrigel (BD Biosciences, San Jose, CA) and injected
subcutaneously into the right flank of the mice, one
injection per animal, on Day 1. Tumors were measured
with digital calipers and tumor volume was calculated
using the formula A
2xB/2, where A is the short diameter
of the tumor, and B is the long diameter perpendicular
to A. Mice in all studies were weighed and assessed for
general health once a week, and tumors were measured
twice a week. Animal experiments were performed
according to the National Institutes of Health Guide for
the Care and Use of Experimental Animals and
approved by the Institutional Animal Care and Use
Committee (IACUC APN 08607). Animals were sacri-
ficed according to humane guidelines provided by the
IACUC. The study endpoint was Day 37, when several
tumor volumes were estimated at nearly 10% of the ani-
mals’ weight. Tumors were removed and measured in
three dimensions, and weighed to validate the accuracy
of the in situ measurements.
Statistics
T h ex e n o g r a f ts t u d yu s e do n et a i lS t u d e n t ’st - t e s t
assuming equal variance. In figures, all error bars repre-
sent standard error of the mean (SEM).
Results
Medulloblastoma cells in culture are exquisitely sensitive
to pharmacological inhibitors of NFB
Several pharmacological inhibitors of the NFB pathway
were tested on multiple human medulloblastoma cell
lines (Figure 1A). After three days, less than 20% of cells
survived exposure to nanomolar concentrations of pyr-
rolidine dithiocarbamate (PDTC), diethyldithiocarbamate
(DDTC), and bortezomib (BTZ). Cells were also sensi-
tive to micromolar concentrations of curcumin (CURC)
and sulfasalazine (SAS). This inhibition of cell growth
was dose dependent and persistent over time: using
PDTC at the IC90, Daoy and D425 cell lines failed to
proliferate after three days following a single administra-
tion of drug at day zero (Figure 1B).
To determine the nature of PDTC-induced inhibition
of cell growth, cells were assayed for apoptosis. Cells
were treated with PDTC at varying concentrations for 3
days and then stained with annexin V, a protein that
binds to cell surface phosphatidylserine, which is
expressed when cells undergo apoptotic cell death.
Staining demonstrated that the cause of decreased cell
number seen in dose response curves is largely due to
apoptosis (Figure 1C). This was true for all medulloblas-
toma cell lines tested.
Interestingly, U-87MG glioma cells treated with
DDTC and PDTC were insensitive to both drugs at con-
centrations <1,000 nM (Figure 2A). Only concentrations
>10 μM inhibited U87 proliferation. Thus, medulloblas-
toma cells are far more sensitive to NFB inhibition
than another malignant brain tumor cell line. There are
reports of NFB constitutive activity in glioma [17,18]
and reports to the contrary [19,20]. U-87MG cells are,
however, very sensitive to sulfasalazine [20], due to a
mechanism of action separate from its NFB inhibition
(discussed below).
Because NFB is an important signaling pathway in
many homeostatic functions of normal cells, we tested
the effect of an NFB blocker on normal neural stem
cells. Neurospheres acquired from mouse E14 cortical
neural stem cells were treated with a broad range of
PDTC concentrations and evaluated at 24 hours and at
4 days post-treatment. Because these cells grow in
spheres comprising hundreds of cells each, an accurate
cell count was not achieved. However, visual inspection
of spheres shows no morphologically apparent differ-
ence in sphere size, number or integrity at doses of
0.1 μMt o1 0μM. At 100 μM PDTC, a dose that would
be quite toxic to medulloblastoma cells, subtle changes
were detected: there were fewer large spheres, and smal-
ler spheres were less aggregated. At 1mM, all spheres
were smaller and less smooth, suggesting disrupted
adhesion integrity, and free floating cells were more
numerous with a crenated appearance, suggesting cell
death (Additional File 1 B). Western blot analysis of
neurosphere lysates reveals increased cleaved caspase 3
expression after 24 hours of 1 μM PDTC treatment and
a large amount of cleaved caspase 3 expression from
cells treated with >100 μM PDTC. At 4 days, the low
concentration of PDTC (0.5-1 μM) needed to eliminate
most medulloblastoma cells did not have much effect
on growth and survival of nonmalignant mouse neural
stem cells. There was not a substantial increase in
cleaved caspase 3 expression among cells treated with
0-10 μM PDTC (Figure 2B). Taken together, the data
indicate that medulloblastoma cells are exquisitely sensi-
tive to NFB blockade and will not proliferate when
exposed to NFB inhibitors at concentrations that do
not affect normal neural stem cells or other malignant
cell lines.
Nuclear p65 protein expression is inducible but not
constitutive at high levels in cultured medulloblastoma
cells
The sensitivity of medulloblastoma cells to inhibitors
suggests that NFB is an important and probably
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tumors. In cultured cells, however, significant p65 pro-
tein expression in the nucleus was only apparent with
stimulation by tumor necrosis factor alpha (TNFa).
Maximal response is seen at 30 minutes after applica-
tion of TNFa.p 6 5e x p r e s s i o nr e t u r n st ob a s e l i n eb y
four hours. IB expression in the cytoplasm decreased
with TNFa stimulation, as expected [11] (Figure 3A).
These results suggest that p65 is not highly constitu-
tively active in cultured cells without application of
external stress, though a low level of baseline expression
is evident. The reason these cells are so sensitive to
NFB blockade is unclear but may be due to a reliance
on low level function which is sensitivity to any pertur-
bations in the pathway. It is possible these changes are
too subtle to detect by Western blotting.
Xenograft flank tumors from medulloblastoma cell lines
over express both nuclear and cytoplasmic p65
Because p65 protein is inducible with TNFa stimulation
in cultured cells, but its activity was difficult to detect in
resting cells, we reasoned that NFB signaling in tissue
may be dependent on factors not available in culture.
We prepared tumors from cell lines to test this idea.
D425 cells were used to establish flank tumors in athy-
mic mice. Nuclear extracts from tumors show enhanced
nuclear p65 by Western compared to the same cell lines
in culture. The cytoplasmic p65 is extremely abundant
when D425 cells are grown in mice as flank tumors,
indicating that characteristics of the tumor environment
stimulate robust NFB signaling. Figure 3B shows Wes-
tern data from one representative tumor; 3 additional
tumors and 3 more passages of D425 cells were tested
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Figure 1 Pharmacological inhibition of NFB in medulloblastoma cell lines.A :D o s eD e p e n d e n tS u r v i v a l :D o s er e s p o n s eo f
medulloblastoma cell lines (cell number normalized to control) to NFB inhibitors: pyrrolidine dithiocarbamate = PDTC, diethyldithiocarbamate =
DDTC, sulfasalazine = SAS, curcumin = CURC, bortezomib = BTZ. (n = 3) Drug applied on day 0, cell count day 3 B: Time dependent survival:
Time course of Daoy and D425 cells in response to IC90 values of PDTC (cell number normalized to control). Daoy 325 nM PDTC; D425 350 nM
PDTC. (n = 3) Drug was applied only once on Day 0 C: Apoptosis: Annexin V staining for apoptosis in cell lines after 3 days in culture with
designated concentrations of PDTC (n = 3 or more)
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used to develop flank tumors and demonstrated the
same dramatic upregulation of p65 in vivo (Figure 3C).
NFB is over expressed in human and mouse
medulloblastoma tumors
Primary tumor samples from three cases of medulloblas-
toma were obtained, and staining with hematoxylin and
eosin (H&E) was used to identify the location of tumor
cells (not shown). Immunohistochemical (IHC) staining
showed that at least 50-90% of evaluable tumor cells
strongly express phos(S276) p65, the nuclear transcrip-
tionally active form of p65 (Figure 4A-C). To corrobo-
rate this IHC finding, total tissue lysates from 3 more
human primary medulloblastoma tumor samples were
probed by Western blotting for total p65 and phos
(S276)p65. Controls for this assay are human cerebral
cortex and cerebellum from adult autopsy tissue. These
human tumor samples showed higher levels of total and
phosphorylated p65 compared to non-malignant tissue.
Additionally, tissue from a brain tumor that developed
in a Smo/Smo transgenic medulloblastoma mouse [4]
showed an overabundance of p65 and phos(S276) p65
compared to a wild type C57Bl/6 mouse cerebellum
(Figure 4D).
NFB signaling is important in normal growth control of
medulloblastoma cells in vitro and in vivo
Medulloblastoma cells in culture grow poorly and
undergo apoptotic cell death in response to drugs that
inhibit the NFB pathway. However, no drug tested is
specific for NFB alone. To more specifically determine
the necessity of normal NFB signaling for survival and
proliferation of medulloblastoma, we genetically
manipulated D425 cells to prevent pathway activity. A
dominant negative form of IB (dnIB) was constructed.
The dominant negative protein has two mutations that
eliminate phosphorylation sites, preventing IBf r o m
being phosphorylated. The resulting protein cannot be
degraded, so it can create a chronic blockade of p65
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Page 7 of 13nuclear translocation, thus blocking NFB -driven tran-
scription. The dnIB construct was prepared in the
inducible “Tet-off” system, which inhibits expression of
the construct in the presence of doxycycline (DOX), but
which induces full expression once the DOX is removed
(No DOX). Inducing the construct by removing DOX
was done to ensure that any effects were due to the
construct alone and not to DOX.
A stable cell line containing the dnIBc o n s t r u c t ,
4H10, shows expression of p65 and phos(S536)p65 that
can be stimulated with TNFa in much the way unal-
tered cultured medulloblastoma cells do (Figure 5A).
However, when the construct was induced by washing
away DOX, less nuclear p65 (specifically the transcrip-
tionally active phosphorylated form) is evident, and
there is not a significant decrease in cytoplasmic p65
with TNFa stimulation. This is consistent with a block
of nuclear translocation. We then tested the biological
activity of the construct. A reporter plasmid, p5x NFB
-Luc, bearing five copies of the NFBp r o m o t e r
upstream of a luciferase reporter gene, was transiently
transfected, and cells were stimulated with TNFa.D O X
cells had a 13-fold increase in reporter expression upon
TNFa stimulation, compared to only a 6-fold increase
in No DOX cells (Additional File 1 C).
One possible explanation for the remaining NFB
activity in the induced (No DOX) 4H10 cells is that the
dominant negative could be toxic to the cells and per-
haps they are able to escape its effects despite stable
drug selection. The co-expressed AcGFP was detected
in only ~50% of induced cells analyzed by FACS (data
not shown), despite rigorous drug selection. Another
possibility involves potential overlap via the noncanoni-
cal NFkB pathway [6], which has not been investigated
in this model.
The 4H10 cells containing inducible dnIB were used
to create flank xenograft tumors in athymic mice. Cells
were grown with DOX in the medium, and 24 hours
before flank implantation, half the cells were washed
free of DOX. Mice that were assigned to the DOX arm
were injected with cells continually exposed to DOX
and were fed a diet containing DOX. Mice assigned to
the No DOX arm were injected with cells that had
DOX removed from the medium, and mice were given
A
p65
phos p65
IκB
Daoy
n
u
c
c
y
t
o
actin
C
B
histone
D425
nuc cyto
tubulin
FT CC FT CC
p65
Daoy D283 Daoy D283
cyto nuc
FT CC FT CC FT CC FT CC
actin
p65
Hrs
Figure 3 NFB expression in medulloblastoma in vitro and in vivo. A: Activation of NFB: Timecourse of NFB activation by 15 ng/mL TNFa
in Daoy cells by probing for nuclear p65, nuclear phos(S276) p65, & cytoplasmic IB. nuc = nuclear fraction, cyto = cytoplasmic fraction. p65
band ~70kD; phos p65 band ~97kD; IB band ~37kD B: Tissue Expression: expression of NFB p65 subunit in D425 cells grown in culture (CC)
compared to D425 cells grown in a flank tumor model (FT). Nuclear (nuc) and cytoplasmic (cyto) fractions were separated by differential
centrifugation following lysis by nitrogen cavitation as described. C: p65 expression by Western in cultured cells vs flank tumors for 2 additional
cell lines. CC = cells in culture, FT = flank tumor. p65 band~60kD. Extracts were obtained using the NE-PER kit as described.
Spiller et al. BMC Cancer 2011, 11:136
http://www.biomedcentral.com/1471-2407/11/136
Page 8 of 13regular food. There were no apparent differences in the
general health or food intake between the groups. Two
mice initially had small tumors that after 5 weeks were
imperceptible, and both were on the No DOX arm. One
mouse on the DOX arm had a very rapidly growing
tumor and had to be euthanized at four weeks, so it was
excluded from data analysis. One mouse in the DOX
arm died unexpectedly early in the trial and was also
excluded. By study end at 5 weeks, the No DOX group
had an average tumor volume 40% smaller than the
DOX average volume (p < 0.03) based on measurements
in live animals (Figure 5B). Tumors were removed,
weighed, and remeasured, this time in 3 dimensions,
and results were the same (Figure 5C). Western analysis
on tumor tissue lysates confirms that the DOX tumors
had higher phos(S276)p65 expression than No DOX
tumors (expressing dnIB). A representative Western of
three animals from each arm of the study is shown in
Figure 5D. Westerns of tumors from all remaining ani-
mals were consistent with this finding.
Discussion
Our results indicate that NFB is over-active in medul-
loblastoma, the most common malignant brain tumor in
children. This was demonstrated in all six primary
tumors examined by either IHC or western, as well as
in xenografts of three human medulloblastoma cell
lines. Further, limiting NFB activity using a variety of
pharmacological agents that target different steps of the
pathway has a negative effect on tumor cell line viability
and growth. These results implicate NFB signaling as a
necessary component of medulloblastoma tumor main-
tenance and tumor progression. We did not investigate
the role of NFB in tumorigenesis.
The five pharmacologic NFB inhibitors we tested have
different targets for disrupting NFB signaling. Curcumin
acts on IKK [37,38], a signal-dependent kinase, to block
phosphorylation of p65 and IBa by generation of reac-
tive oxygen species [39]. Sulfasalazine inhibits phosphor-
ylation of IBa by blocking IKK activity [40,41]. Another
activity of sulfasalazine is inhibition of system Xc(-), an
A C
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Figure 4 Primary tumor expression of NFB. A-C: Phosphorylated p65 in primary medulloblastoma: immunohistochemical staining of three
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positivity in addition to tumor cells. D: Expression of p65 and phos (S536) p65 in normal brain and tumor in humans [CX = cerebral cortex, CB1
and CB2 = cerebella from 2 different autopsy specimens; mb4, mb2, mb8 = surgical samples of 3 different patient medulloblastoma tumors]
along with normal C57Bl/6 mouse cerebellum (CB) compared to Smo/Smo mouse (Smo) cerebellar tumor.
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Page 9 of 13amino acid transporter essential for cystine uptake and
survival of glioblastoma [20]. We ruled out system Xc(-)
as the mechanism of action in medulloblastoma cell lines
by treating with S-4-CPG, a specific system Xc(-) inhibi-
tor, with no effect on cell survival (data not shown). Bor-
tezomib inhibits the ubiquitin-proteasome, thereby
preventing IB degradation [32]. Dithiocarbamates are
metal chelators, antioxidants, proteasome inhibitors
(under certain conditions) [42,43], and potent NFB inhi-
bitors [44], functioning to block IBa release from NFB
in the cytoplasm. PDTC causes oxidation of NFB,
thereby decreasing DNA binding [45]. None of these
agents is specific to NFB but strike different targets
within the pathway. Because these agents have many
activities, yet have NFB inhibition in common, we con-
clude that the commonality of tumor cell sensitivity to all
of them lies in the NFB pathway [10].
Because of the lack of specific pharmacologic inhibi-
tors, we investigated a genetic blockade of the canonical
NFkB pathway. The inducible dnIkB construct reduced
growth of cells in culture by only about 25% of parent
D425 cells, on average, as did a second dominant nega-
tive cell line established in Daoy parent cells (data not
shown). Furthermore, the dnIB in D425 cell xenograft
tumors had a modest impact on tumor growth but did
not completely eliminate it in most animals. It is likely,
given these results, that pharmacologic inhibitors are
more effective because they target NFB-dependent as
well as NFkB-independent pathways.
The role of NFB has been extensively studied in neu-
rons. p65/p50 heterodimers have been isolated from
synapses [21]; neurotransmitters are among the many
activators of NFB [22]. Despite their neuronal lineage,
medulloblastoma cells do not fire action potentials [46],
so the role neurotransmitters play in NFB signaling in
medulloblastoma is not known. NFB is activated by
Ca
2+ influx via L-type Ca
2+ channels, but medulloblasto-
mas do not express these channels, at least in vitro [46].
Therefore, neuronal physiology has not been helpful in
clarifying the role of NFB in medulloblastoma.
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Page 10 of 13However, it is clear that NFB is activated in neurons in
a variety of pathologic brain conditions. Neurons
become more vulnerable to injury when NFBi si n h i b -
ited [23-25]. Thus, NFB may be one mechanism used
by neurons to survive insult [23]. We demonstrate that
medulloblastoma cells are much more sensitive to NFB
inhibitors than normal immature neurons (Figure 2B),
which would suggest that medulloblastoma cells rely on
downstream targets, such as antiapoptotic genes, when
they are physiologically challenged. In contrast, neuro-
protection has also been reported by blocking NFBi n
cerebellar granule neurons [25]. Indeed, inhibition of
NFB activity has been shown to promote as well as
protect against neurotoxicity [25,26]. NFB plays a role
in cerebellar development during the first 1-2 weeks of
life in mice and rats, and probably the first several
months in humans [27,28]. It is suspected that NFB
signaling is involved in early granule neuron migration
[27]. More studies are needed to determine whether
NFB inhibition could prevent medulloblastoma cell
migration or metastatic spread, especially because this is
a feature of medulloblastoma that is not very well
understood.
Constitutive NFB activity has been reported in adult
malignant brain tumors and a number of other solid
tumors in adulthood. There has been a focus on evi-
dence relating chronic inflammation to cancer in recent
years [10,29], including the role that NFB plays in
each. More specifically, neural stem cell inflammation
and dysregulation of NFB signaling could be a source
of tumorigenesis in the brain [29]. However, the link
between inflammation and cancer will be much harder
to make in pediatric cases, because most tumors present
in children who have no history of illness and no clinical
inflammation. In fact, H&E staining of the three primary
tumors presented here showed no inflammatory cell
infiltration (data not shown). Yet, NFB still seems to
be significant in pediatric cancers. Retinoblastoma, a
cancer of primitive neuroectodermal cells of the retina
that occurs in very young children, is dependent on
NFB activity for survival [30]. Neuroblastoma, a tumor
of children arising from neural crest cells, displays a
spectrum of outcomes from spontaneous regression to
rapid metastatic spread resistant to the most aggressive
therapeutic interventions. Some neuroblastoma cell lines
show high NFB activity with dramatic response to its
inhibition [31,32]. Additionally, high NFB levels were
found in rhabdomyosarcoma and Ewing’sf a m i l yo f
tumors [33,34]. There are two reported investigations of
NFB in medulloblastoma. The first examined methio-
nine stress in brain tumors, and saw that methionine
deprivation resulted in NFB activation in one medullo-
blastoma cell line, causing rapid cell death [35]. This is
consistent with our finding that NFB is active and can
be upregulated in cell lines. Specifically, we showed a
large increase in detectable p65 when cultured cells are
implanted as xenografts, compared to the same cells in
culture. The other report indicates that 2-methylestro-
diol, an inhibitor of NFB, is pro-apoptotic in three
medulloblastoma cell lines [36]. This result is very con-
sistent with our data using five inhibitors of NFBi n
multiple cell lines.
The clinical relevance of associating NFB activity
with malignancy may be substantial. First, there are a
number of US Food and Drug Administration-approved
or experimental drugs available that act to inhibit the
NFB signaling pathway. There are other anti-apoptotic
signals in play in solid tumors, such that inhibition of
NFB is unlikely to change the course of the tumor
when used as the sole anticancer therapy. Yet one must
keep in mind that multi-drug therapy has long been the
approach to cancer care because of this very issue. Sec-
ond, blocking NFB generally enhances the responsive-
ness of tumors to traditional chemotherapy [47,48].
This, however, is also not straightforward. NFB activity
is necessary for paclitaxel and doxorubicin cytotoxicity
[49,50], and some traditional chemotherapies activate
NFB signaling [51,52]. Conversely, apoptosis induced
by irinotecan, daunorubicin and cisplatin therapies is
reportedly enhanced by blocking NFB [47,49,53]. Once
again the complexity of NFB -modulated apoptosis is
revealed, highlighting the importance of the proper bal-
ance of NFB activity in individual tumors treated with
specific chemotherapeutic agents. Cisplatin is an impor-
tant anti-medulloblastoma drug; studies need to be per-
formed to evaluate the effect of NFBb l o c k a d eo nt h e
chemosensitivity of medulloblastoma to cisplatin.
Finally, radiation is the most effective therapy for
medulloblastoma and is known to activate NFB. Yet
inhibition of NFB with curcumin or other pharmacolo-
gical and molecular inhibitors increases radiosensitivity
in glioblastoma [54,55] and fibrosarcoma cells [49].
Increasing medulloblastoma sensitivity to radiation,
especially if normal neuron sensitivity is unchanged,
could dramatically change current treatment and
improve outcomes for patients with medulloblastoma.
Conclusions
We conclude that NFB signaling may turn out to be
extensively involved in medulloblastoma. Further suc-
cessful treatment of medulloblastoma may rely on
proper management of the NFB pathway to ensure
efficacy of current therapies. Much more work needs to
be done to understand whether or not therapeutic
manipulation of NFB cellular regulation can be useful
in a clinical setting.
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Page 11 of 13Additional material
Additional File 1: Supplemental figure. A - Construct for Tet-off dnIB
used in D425 cells to create 4H10 cells B - Neurospheres cultured in
medium containing PDTC for 24 hours (photos at 10X) C - Transient
transfection with p5X NFB -Luc demonstrates diminished NFB
induction with dnIB construct activated in 4H10 cells by removing DOX.
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